Houston-based TYBR Health, a medtech and orthopedic regenerative medicine company, has secured $30 million in a Series A financing round.
The company will use the funds to expand commercial access to its FDA-approved B3 GEL System, broaden its product indications and run clinical studies evaluating tissue protection during orthopedic surgery, according to a July 21 news release from TYBR Health.
The B3 GEL System is a flowable extracellular matrix hydrogel designed to protect tendons, ligaments, muscles and the surrounding soft tissue while they heal. Since its launch, the system has been used in hand, wrist, shoulder, foot and ankle, and sports medicine procedures.
Vensana Capital and Mutual Capital Partners led the financing round with participation from Neovate Capital Partners and existing investors, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.